AFP and hepatocellular carcinoma: In the subgroup analysis, we found that HCC patients with AFP<400, Child-Pugh class A, without macroscopic portal vein invasion, BCLC stage A or B, without extrahepatic metastasis, and a single progression pattern could benefit from the single drug switching strategy.